These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36692913)

  • 41. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Developing a rapid-response program for health system decision-makers in Canada: findings from an issue brief and stakeholder dialogue.
    Wilson MG; Lavis JN; Gauvin FP
    Syst Rev; 2015 Mar; 4():25. PubMed ID: 25875495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tackling rare diseases at European level: why do we need a harmonized framework?
    Taruscio D; Trama A; Stefanov R
    Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisions.
    Gauvreau CL; Wight L; Subasri M; Palmer A; Hayeems R; Croker A; Abelson J; Fraser B; Bombard Y; Moore Hepburn C; Wilson MG; Denburg A
    Health Expect; 2023 Apr; 26(2):715-727. PubMed ID: 36639959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Assessment Framework for e-Mental Health Apps in Canada: Results of a Modified Delphi Process.
    Zelmer J; van Hoof K; Notarianni M; van Mierlo T; Schellenberg M; Tannenbaum C
    JMIR Mhealth Uhealth; 2018 Jul; 6(7):e10016. PubMed ID: 29986846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
    Masucci L; Beca J; Sabharwal M; Hoch JS
    Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?
    Jenei K; Gyawali B
    Healthc Pap; 2023 Jan; 21(1):44-51. PubMed ID: 36692916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 49. Food for Thought: A Dissonance Between Healthcare Utilization Costs and Research Funding for Eating Disorders in Canada.
    Stone KD; Dimitropoulos G; MacMaster FP
    J Can Acad Child Adolesc Psychiatry; 2021 Aug; 30(3):197-203. PubMed ID: 34381512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper.
    Zozaya N; Villaseca J; Abdalla F; Ancochea A; Málaga I; Trapero-Bertran M; Martín-Sobrino N; Delgado O; Ferré P; Hidalgo-Vega A
    Orphanet J Rare Dis; 2023 Feb; 18(1):41. PubMed ID: 36823598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oncology drug health technology assessment recommendations: Canadian versus UK experiences.
    Chabot I; Rocchi A
    Clinicoecon Outcomes Res; 2014; 6():357-67. PubMed ID: 25075196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orphan drugs: expensive yet necessary.
    Hyry HI; Roos JC; Cox TM
    QJM; 2015 Apr; 108(4):269-72. PubMed ID: 25434052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
    Husereau D; Dempster W; Blanchard A; Chambers J
    Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Canadian Health Care System: Who Should Pay for All Medically Beneficial Treatments? A Burning Issue.
    Chowdhury MZI; Chowdhury MA
    Int J Health Serv; 2018 Apr; 48(2):289-301. PubMed ID: 29095077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does Introducing Public Funding for Allied Health Psychotherapy Lead to Reductions in Private Insurance Claims? Lessons for Canada from the Australian Experience.
    Diminic S; Bartram M
    Can J Psychiatry; 2019 Jan; 64(1):68-76. PubMed ID: 29925270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implementing Indigenous community control in health care: lessons from Canada.
    Lavoie JG; Dwyer J
    Aust Health Rev; 2016 Sep; 40(4):453-458. PubMed ID: 26553422
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disability in two health care systems: access, quality, satisfaction, and physician contacts among working-age Canadians and Americans with disabilities.
    Gulley SP; Altman BM
    Disabil Health J; 2008 Oct; 1(4):196-208. PubMed ID: 21122730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pan-Canadian consensus recommendations for proton beam therapy access in Canada.
    Mitera G; Tsang D; McCurdy B; Goddard K; Ebacher A; Craig T; Greenland J; Kentish S; Koul R; Logie N; Morneau M; Morrison A; Pan L; Pantarotto J; Foxcroft S; Sussman J; Thompson R; Tyldesley S; Wright P; Hicks S; Brown E; Patel S;
    Radiother Oncol; 2022 Nov; 176():228-233. PubMed ID: 36228758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.